Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, Bernard, Wanner, Christoph, Lachin, John M., Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa +4 more·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1504720

Cited by (12,156)

Items 11,401–11,500 of 12,156

Additional file 1 of Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction: a case–control study in individuals aged 65–80 years
Yousuke Sugita, Ito, Katsuhiko, Yui Yoshioka · 2023 · Figshare
Additional file 1 of Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
Jeong, Su Jin, Seung Eun Lee, Dong Hyun Shin, Park, Ie Byung, Lee, Hui Seung, Kim, Kyoung-Ah · 2021 · Figshare
Additional file 3 of Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
Shimizu, Wataru, Yoshiaki Kubota, Yu Hoshika, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu‐ki Iwasaki, Yamamoto, Takeshi, Hitoshi Takano et al. · 2020 · Figshare
Additional file 2 of Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, Melanie J., Drexel, Heinz, François R. Jornayvaz, Zoltan Pataky, Seferović, Petar M., Wanner, Christoph · 2022 · Figshare
Additional file 1 of Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
Tsai, Pei-Chien, Chuang, Wei-Jung, Albert Min‐Shan Ko, Chen, Jui-Shuan, Chiu, Cheng-Hsun, Chen, Chun-Han, Yung‐Hsin Yeh · 2024 · Figshare
Additional file 5 of Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial
Naoto Katakami, Mita, Tomoya, Yoshii, Hidenori, Toshihiko Shiraiwa, Yasuda, Tetsuyuki, Okada, Yosuke, Akira Kurozumi, Masahiro Hatazaki, Kaneto, Hideaki, Takeshi Osonoi et al. · 2023 · Figshare
Additional file 1 of Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis
Veronika A. Myasoedova, Valentina Parisi, Donato Moschetta, Vincenza Valerio, Maddalena Conte, Ilaria Massaiu, Michele Bozzi, Fabrizio Celeste, Dario Leosco, Guido Iaccarino et al. · 2024 · Figshare
Additional file 1 of The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
Massar Omar, Jensen, Jesper, Caroline Kistorp, Højlund, Kurt, Videbæk, Lars, Christian Tuxen, Julie Hempel Larsen, Andersen, Camilla F., Gustafsson, Finn, Køber, Lars et al. · 2022 · Figshare
Additional file 1 of Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study
Vencio, Sérgio, André Gustavo Daher Vianna, Mariana Arruda Camara Ferreira da Silva, Precoma, Dalton Bertolim · 2022 · Figshare
Additional file 1 of Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
Meir Schechter, Cheli Melzer Cohen, Ilan Yanuv, Aliza Rozenberg, Chodick, Gabriel, Johan Bodegård, Leiter, Lawrence A., Verma, Subodh, Hiddo J. Lambers-Heerspink, Avraham Karasik et al. · 2022 · Figshare
Additional file 2 of Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Ahmad, Aftab, Hani Mohamed Sabbour · 2024 · Figshare
Additional file 1 of Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
Sin‐Hee Park, Eugenia Belcastro, Hira Hasan, Kensuke Matsushita, Benjamin Marchandot, Malak Abbas, Florence Toti, Cyril Auger, Laurence Jesel, Patrick Ohlmann et al. · 2021 · Figshare
Additional file 1 of Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
Bénédicte Gaborit, Patricia Ancel, Amany Abdullah, Maurice, F., Inès Abdesselam, Andreea Calen, Astrid Soghomonian, Houssays, M., Isabelle Varlet, Eisinger, M. et al. · 2021 · Figshare
Additional file 1 of Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
Hwang, In-Chang, Goo‐Yeong Cho, Yoon, Yeonyee E., Park, Jin Joo, Park, Jun-Bean, Lee, Seung-Pyo, Kim, Hyung-Kwan, Yong-Jin Kim, Sohn, Dae-Won · 2020 · Figshare
Additional file 6 of Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
Naoto Katakami, Mita, Tomoya, Yoshii, Hidenori, Toshihiko Shiraiwa, Yasuda, Tetsuyuki, Okada, Yosuke, Torimoto, Keiichi, Yutaka Umayahara, Kaneto, Hideaki, Takeshi Osonoi et al. · 2021 · Figshare
Additional file 4 of Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
Tsai, Pei-Chien, Chuang, Wei-Jung, Albert Min‐Shan Ko, Chen, Jui-Shuan, Chiu, Cheng-Hsun, Chen, Chun-Han, Yung‐Hsin Yeh · 2024 · Figshare
Additional file 1 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
Yi‐Hsin Chan, Chao, Tze-Fan, Chen, Shao-Wei, Lee, Hsin-Fu, Li, Pei-Ru, Chen, Wei-Min, Yung‐Hsin Yeh, Chi-Tai Kuo, See, Lai-Chu, Gregory Y.H. Lip · 2022 · Figshare
Additional file 14 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Liu, Jia, Chang, Xiaona, Xiaoyu Ding, Xueqing He, Jiaxuan Wang, Wang, Guang · 2024 · Figshare
Additional file 7 of Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial
Naoto Katakami, Mita, Tomoya, Yoshii, Hidenori, Toshihiko Shiraiwa, Yasuda, Tetsuyuki, Okada, Yosuke, Akira Kurozumi, Masahiro Hatazaki, Kaneto, Hideaki, Takeshi Osonoi et al. · 2023 · Figshare
Additional file 1 of Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
Thein, David, Mia Nielsen Christiansen, Mogensen, Ulrik Madvig, Johan Skov Bundgaard, Rasmus Rørth, Christian Madelaire, Fosbøl, Emil Loldrup, Schou, Morten, Torp-Pedersen, Christian, Gislason, Gunnar et al. · 2020 · Figshare
Additional file 2 of Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
William Hinton, Michael D. Feher, Neil M. Munro, Joy, Mark, de Lusignan, Simon · 2021 · Figshare
Additional file 2 of Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial
Lorenzo Nesti, N. Pugliese, Paolo Sciuto, Trico, Domenico, Angela Dardano, Baldi, Simona, Silvia Pinnola, Iacopo Fabiani, Vitantonio Di Bello, Natali, Andrea · 2022 · Figshare
Additional file 4 of Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
Shimizu, Wataru, Yoshiaki Kubota, Yu Hoshika, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu‐ki Iwasaki, Yamamoto, Takeshi, Takano, Hitoshi et al. · 2020 · Figshare
Additional file 8 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Liu, Jia, Chang, Xiaona, Xiaoyu Ding, Xueqing He, Jiaxuan Wang, Wang, Guang · 2024 · Figshare
Additional file 7 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Yi-lin, Xiaozhuo Xu, Liu, Jing, Wang, Pin-yao, Wang, Xue-li, Feng, Hong-lin, Liu, Cheng-jiang, Han, Xu · 2024 · Figshare
Additional file 2 of Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Mafalda Ramos, Men, Peng, Wang, Xu, Ustyugova, Anastasia, Mark Lamotte · 2021 · Figshare
Additional file 4 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Yi-lin, Xiaozhuo Xu, Liu, Jing, Wang, Pin-yao, Wang, Xue-li, Feng, Hong-lin, Liu, Cheng-jiang, Han, Xu · 2024 · Figshare
Additional file 1 of Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
Tanaka, Atsushi, Toyoda, Shigeru, Imai, Takumi, Shiina, Kazuki, Hirofumi Tomiyama, Yasushi Matsuzawa, Okumura, Takahiro, Kanzaki, Yumiko, Katsuya Onishi, Kiyosue, Arihiro et al. · 2021 · Figshare
Additional file 1 of Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
DAVID H. FITCHETT, Zinman, Bernard, Inzucchi, Silvio E., Wanner, Christoph, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin, Lund, Søren S. · 2024 · Figshare
Additional file 1 of Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials
Masashi Hasebe, Satoshi Yoshiji, Yamato Keidai, Hiroto Minamino, Murakami, Takaaki, Tanaka, Daisuke, Fujita, Yoshihito, Norio Harada, Akihiro Hamasaki, Inagaki, Nobuya · 2024 · Figshare
Additional file 11 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Liu, Jia, Chang, Xiaona, Xiaoyu Ding, Xueqing He, Jiaxuan Wang, Wang, Guang · 2024 · Figshare
Additional file 1 of A systematic review of sodium-glucose cotransporter 2 inhibitors and renal profiles among Japanese patients with type 2 diabetes mellitus
Junichi Mukai, Nakaba Okamura, Saito, Yuki, Rie Kubota · 2024 · Figshare
Additional file 1 of Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Vistisen, Dorte, Bendix Carstensen, Elisabetta Patorno, Stefanie Lanzinger, Elise Chia-Hui Tan, Yabe, Daisuke, Kim, Dae Jung, Wayne Huey‐Herng Sheu, Cheli Melzer Cohen, Holl, Reinhard W. et al. · 2024 · Figshare
Additional file 1 of Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Chen, Jui-Yi, Pan, Heng-Chih, Shiao, Chih-Chung, Chuang, Min-Hsiang, Chun Yin See, Yeh, Tzu-Hsuan, Yang, Yafei, Chu, Wen-Kai, Wu, Vin-Cent · 2024 · Figshare
Additional file 13 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Jia Liu, Chang, Xiaona, Xiaoyu Ding, Xueqing He, Jiaxuan Wang, Wang, Guang · 2024 · Figshare
Additional file 4 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Liu, Jia, Chang, Xiaona, Xiaoyu Ding, Xueqing He, Jiaxuan Wang, Wang, Guang · 2024 · Figshare
Additional file 3 of Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial
Fujiki, Shinya, Iijima, Kenichi, Nakagawa, Yoshihisa, Kazuyoshi Takahashi, Masaaki Okabe, Kusano, Kengo, Shingen Owada, Kondo, Yusuke, Tsujita, Kenichi, Shimizu, Wataru et al. · 2024 · Figshare
Additional file 2 of Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial
Fujiki, Shinya, Iijima, Kenichi, Nakagawa, Yoshihisa, Kazuyoshi Takahashi, Masaaki Okabe, Kusano, Kengo, Shingen Owada, Kondo, Yusuke, Tsujita, Kenichi, Shimizu, Wataru et al. · 2024 · Figshare
Additional file 1 of ProtecT-2-D trial protocol: cardiovascular protection in patients with type 2 diabetes and established heart and/or vascular disease at a cardio-metabolic clinic—a randomized controlled trial
Katrine Schultz Overgaard, Mohamed, Roda Abdulkadir, Thomas Rueskov Andersen, Jess Lambrechtsen, Kenneth Egstrup, Søren Auscher · 2024 · Figshare
Additional file 2 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Liu, Jia, Chang, Xiaona, Xiaoyu Ding, Xueqing He, Jiaxuan Wang, Wang, Guang · 2024 · Figshare
Additional file 1 of Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study
Sohee Park, Jeong, Han Eol, Lee, Hyesung, You, Seng Chan, Shin, Ju-Young · 2024 · Figshare
Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin versus Metformin Alone: A Randomized Open Label Clinical Study. The MAGNNIFY Trial.
Anna Paula Guerrero-Castillo, Alberto Sigfrido Benítez-Rentería, María Guadalupe López-Carrasco, Daniel Cuevas-Ramos, Alejandra Domínguez-Sánchez, Horacio Correa-Carranza, Lucía Palacios-Báez, Sandra Rodríguez-Carranza, Jessica Bahena-López, Griselda Xóchitl Brito-Córdoba et al. · 2024 · Research Square
Additional file 2 of Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
Naoto Katakami, Mita, Tomoya, Yoshii, Hidenori, Toshihiko Shiraiwa, Yasuda, Tetsuyuki, Okada, Yosuke, Torimoto, Keiichi, Yutaka Umayahara, Kaneto, Hideaki, Takeshi Osonoi et al. · 2021 · Figshare
Additional file 1 of Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
Hang‐Long Li, Gregory Y.H. Lip, Qi Feng, Fei, Yue, Tse, Yi-Kei, Wu, Mei-zhen, Ren, Qing-wen, HungFat Tse, Cheung, Bernard-M. Y., Yiu, Kai-Hang · 2021 · Figshare
Additional file 1 of Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
Mansoor Husain, Agostino Consoli, Alessandra De Remigis, Pettersson Meyer, Anna Sina, Rasmussen, Søren, Bain, Stephen · 2022 · Figshare
Additional file 1 of Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease
Susanna R. Stevens, Matthew W. Segar, Pandey, Ambarish, Yuliya V. Lokhnygina, Green, Jennifer B., Darren K. McGuire, Eberhard Standl, Eric David Peterson, Rury R. Holman · 2022 · Figshare
Additional file 1 of CAV3 alleviates diabetic cardiomyopathy via inhibiting NDUFA10-mediated mitochondrial dysfunction
Guo, Ping, Hu, Shuiqing, Liu, Xiaohui · 2024 · Figshare
Additional file 1 of Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry
Arnold, Suzanne V., Jones, Philip G., Michael Beasley, Jeanine M. Cordova, Goyal, Abhinav, Gregg C. Fonarow, LEO J. SEMAN · 2020 · Figshare
Additional file 1 of Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
Moa Lugner, Naveed A. Sattar, Mervete Miftaraj, Ekelund, Jan, Franzén, Stefan, Svensson, Ann-Marie, Eliasson, Björn · 2021 · Figshare
Additional file 4 of Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Mafalda Ramos, Men, Peng, Wang, Xu, Ustyugova, Anastasia, Mark Lamotte · 2021 · Figshare
Additional file 1 of Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes
Lorenzo Nesti, N. Pugliese, Paolo Sciuto, Nicolò De Biase, Matteo Mazzola, Iacopo Fabiani, Trico, Domenico, Stefano Masi, Natali, Andrea · 2021 · Figshare
Additional file 1 of UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
Alistair Roddick, Alexa Wonnacott, David R. Webb, Angela Watt, Watson, Michael A., Staplin, Natalie, Alex Riding, Eirini Lioudaki, Apexa Kuverji, Kossi, Mohsen El et al. · 2023 · Figshare
Additional file 1 of Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
Minji Sohn, Johannes W. Dietrich, Michael Albrecht Nauck, Soo Kyung Lim · 2023 · Figshare
Additional file 1 of Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
Lyu, Young Sang, Seok Kyu Oh, Jin Hwa Kim, Kim, Sang Yong, Myung Ho Jeong · 2024 · Figshare
Additional file 1 of Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
Phyo Than Htoo, Helen Tesfaye, Sebastian Schneeweiß, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz‐Luyet, Julie M. Paik et al. · 2024 · Figshare
Additional file 1 of Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes
Tai, Shi, Liyao Fu, Ningjie Zhang, Rukai Yang, Zhou, Yuying, Xing, Zhenhua, Wang, Yongjun, Zhou, Shenghua · 2022 · Figshare
Additional file 4 of Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Yu, Yi-Wen, Zhao, Xue-Mei, Wang, Yun-Hong, Qiong Zhou, Huang, Yan, Mei Zhai, Zhang, Jian · 2021 · Figshare
Additional file 1 of Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
Naoto Katakami, Mita, Tomoya, Yoshii, Hidenori, Toshihiko Shiraiwa, Yasuda, Tetsuyuki, Okada, Yosuke, Torimoto, Keiichi, Yutaka Umayahara, Kaneto, Hideaki, Takeshi Osonoi et al. · 2021 · Figshare
Additional file 5 of Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
Tsai, Pei-Chien, Chuang, Wei-Jung, Albert Min‐Shan Ko, Chen, Jui-Shuan, Chiu, Cheng-Hsun, Chen, Chun-Han, Yung‐Hsin Yeh · 2024 · Figshare
Additional file 10 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Yi-lin, Xiaozhuo Xu, Liu, Jing, Wang, Pin-yao, Wang, Xue-li, Feng, Hong-lin, Liu, Cheng-jiang, Han, Xu · 2024 · Figshare
Additional file 2 of Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study
Kristian Løkke Funck, Lasse Bjerg, Anders Aasted Isaksen, Annelli Sandbæk, Erik Lerkevang Grove · 2024 · Figshare
Additional file 2 of Celastrol attenuates streptozotocin-induced diabetic cardiomyopathy in mice by inhibiting the ACE / Ang II / AGTR1 signaling pathway
Zhao, Xuyong, Bingwu Huang, Zhang, Jianhua · 2023 · Figshare
Additional file 2 of ProtecT-2-D trial protocol: cardiovascular protection in patients with type 2 diabetes and established heart and/or vascular disease at a cardio-metabolic clinic—a randomized controlled trial
Katrine Schultz Overgaard, Mohamed, Roda Abdulkadir, Thomas Rueskov Andersen, Jess Lambrechtsen, Kenneth Egstrup, Søren Auscher · 2024 · Figshare
Additional file 1 of Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
Shimizu, Wataru, Yoshiaki Kubota, Yu Hoshika, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu‐ki Iwasaki, Yamamoto, Takeshi, Hitoshi Takano et al. · 2020 · Figshare
Additional file 1 of Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
Lim, Jaehyun, Choi, You-Jung, Bong Sung Kim, Rhee, Tae-Min, Lee, Hyun-Jung, Han, Kyung-Do, Park, Jun-Bean, Jin Oh Na, Yong-Jin Kim, Lee, Heesun et al. · 2024 · Figshare
Additional file 1 of The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Ali, Muhammad Usman, Mancini, G. B. John, Donna Fitzpatrick‐Lewis · 2024 · Figshare
Additional file 1 of Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study
Kristian Løkke Funck, Lasse Bjerg, Anders Aasted Isaksen, Annelli Sandbæk, Erik Lerkevang Grove · 2024 · Figshare
Additional file 3 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
Yi‐Hsin Chan, Chao, Tze-Fan, Chen, Shao-Wei, Lee, Hsin-Fu, Li, Pei-Ru, Chen, Wei-Min, Yung‐Hsin Yeh, Chi-Tai Kuo, See, Lai-Chu, Gregory Y.H. Lip · 2022 · VBN Forskningsportal (Aalborg Universitet)
Additional file 7 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Jia Liu, Chang, Xiaona, Xiaoyu Ding, Xueqing He, Jiaxuan Wang, Wang, Guang · 2024 · Figshare
Additional file 1 of Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis
Wang, Chung-An, Lin, Li-Chun, Chen, Jui-Yi, Wang, Wei-Jie, Wu, Vin-Cent · 2024 · Figshare
Additional file 1 of The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator
Roopameera Thirumathyam, Richter, Erik Arne, Gerrit van Hall, Holst, Jens Juul, Mogens Fenger, Jens Peter Gøtze, Ulrik Dixen, Vejlstrup, Niels, Madsbad, Sten, Per Lav Madsen et al. · 2024 · Figshare
Additional file 2 of Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis
Veronika A. Myasoedova, Valentina Parisi, Donato Moschetta, Vincenza Valerio, Maddalena Conte, Ilaria Massaiu, Michele Bozzi, Fabrizio Celeste, Dario Leosco, Guido Iaccarino et al. · 2024 · Figshare
Additional file 1 of Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
Maiorino, Maria Ida, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Chiodini, Paolo, Esposito, Katherine, Dario Giugliano · 2021 · Figshare
Additional file 6 of Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Jia Liu, Chang, Xiaona, Xiaoyu Ding, Xueqing He, Jiaxuan Wang, Wang, Guang · 2024 · Figshare
Additional file 1 of Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom
Vanessa C. Brunetti, Audray St-Jean, Sophie Dell’Aniello et al. · 2022 · Figshare
FIGURE 1 in A new endemic rock Gecko Cnemaspis Strauch 1887 (Squamata: Gekkonidae) from Gunung Jerai, Kedah, northwestern Peninsular Malaysia
Chan Kin Onn, Grismer, Lee, Anuar, Shahrul · 2010 · INFM-OAR (INFN Catania)
Additional file 4 of Are there sex differences in the effect of type 2 diabetes in the incidence and outcomes of myocardial infarction? A matched-pair analysis using hospital discharge data
Lopez-de-Andres, Ana, Rodrigo Jiménez‐García, Valentín Hernández‐Barrera, José María de Miguel-Yanes, Romana Albaladejo‐Vicente, Rosa Villanueva-Orbáiz, David Carabantes-Alarcón, Zamorano-Leon, Jose J., Marta López‐Herránz, de Miguel-Diez, Javier · 2021 · Figshare
Additional file 1 of Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes
Lee, CH, Wu, MZ, Lui, DTW, Chy Fong, Ren, QW, Yu, SY, Yuen, MMA, WS Chow, Huang, JY, Xu, A et al. · 2022 · Figshare
Additional file 1 of The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT)
Ai Haraguchi, Riyoko Shigeno, Ichiro Horie, Shimpei Morimoto, Ayako Ito, Chiba, Ko, Yurika Kawazoe, Shigeki Tashiro, Junya Miyamoto, Sato, Shuntaro et al. · 2020 · Figshare
Additional file 2 of Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
Moa Lugner, Naveed A. Sattar, Mervete Miftaraj, Ekelund, Jan, Franzén, Stefan, Svensson, Ann-Marie, Eliasson, Björn · 2021 · Figshare
Additional file 1 of Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Yamada, Takayuki, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Miyashita, Hirotaka, Mikami, Takahisa, Ueyama, Hiroki, Fujisaki, Tomohiro, Saigusa, Yusuke, Yamaji, Takahiro et al. · 2021 · Figshare
Additional file 3 of Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
Tsai, Ming-Lung, Yuan Lin, Lin, Ming-Shyan, Tsai, Tzu-Hsien, Yang, Ning-I, Wang, Chao-Yung, Hsieh, I-Chang, Hung, Ming-Jui, Chen, Tien-Hsing · 2023 · Figshare
Additional file 1 of The independent association of myocardial extracellular volume and myocardial blood flow with cardiac diastolic function in patients with type 2 diabetes: a prospective cross-sectional cohort study
Annemie Stege Bojer, Martin Heyn Sørensen, Stine H. Madsen, David Andrew Broadbent, Sven Plein, Peter Gæde, Per Lav Madsen · 2024 · Figshare
Additional file 6 of Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Mafalda Ramos, Men, Peng, Wang, Xu, Ustyugova, Anastasia, Mark Lamotte · 2021 · Figshare
Additional file 1 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Yi-lin, Xiaozhuo Xu, Liu, Jing, Wang, Pin-yao, Wang, Xue-li, Feng, Hong-lin, Liu, Cheng-jiang, Han, Xu · 2024 · Figshare
Additional file 1 of The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study
Iwasaki, Yudai, Sasabuchi, Yusuke, Sho Horikita, Furukawa, Taku, Junji Shiotsuka, Lefor Alan K., Masamitsu Sanui · 2022 · Figshare
Additional file 2 of Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Valentina Spigoni, Federica Fantuzzi, Cecilia Carubbi, Giulia Pozzi, Elena Masselli, Gobbi, Giuliana, Anna Solini, Riccardo C. Bonadonna, Dei Cas, Alessandra · 2020 · Figshare
Additional file 4 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
Yi‐Hsin Chan, Chao, Tze-Fan, Chen, Shao-Wei, Lee, Hsin-Fu, Li, Pei-Ru, Chen, Wei-Min, Yung‐Hsin Yeh, Chi-Tai Kuo, See, Lai-Chu, Gregory Y.H. Lip · 2022 · VBN Forskningsportal (Aalborg Universitet)
Additional file 8 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Yi-lin, Xiaozhuo Xu, Liu, Jing, Wang, Pin-yao, Wang, Xue-li, Feng, Hong-lin, Liu, Cheng-jiang, Han, Xu · 2024 · Figshare
Additional file 1 of The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study
Goldman, Adam, Boris Fishman, Gilad Twig, Emanuel Raschi, Tali Cukierman‐Yaffe, Yonatan Moshkovits, Alon Pomerantz, Ilan Ben‐Zvi, Rachel S. Dankner, Elad Maor · 2024 · Figshare
Additional file 9 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Yi-lin, Xiaozhuo Xu, Liu, Jing, Wang, Pin-yao, Wang, Xue-li, Feng, Hong-lin, Liu, Cheng-jiang, Han, Xu · 2024 · Figshare
Additional file 1 of Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis
Liu, Tao, Zeyuan Fan, Xiao, Bing, He, Chang, Shicong Wang · 2024 · Figshare
Additional file 1 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
Meir Schechter, Cheli Melzer Cohen, Aliza Rozenberg, Ilan Yanuv, Chodick, Gabriel, Karasik, Avraham, Kosiborod, Mikhail, Ofri Mosenzon · 2021 · Figshare
Additional file 1 of Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ
Junpei Sanada, Tomohiko Kimura, Masashi Shimoda, Yuichiro Iwamoto, Hideyuki Iwamoto, Kazunori Dan, Yoshiro Fushimi, Yukino Katakura, Yuka Nogami, Yoshiko Shirakiya et al. · 2024 · Figshare
Additional file 1 of Empagliflozin mitigates methotrexate-induced nephrotoxicity in male albino rats: insights on the crosstalk of AMPK/Nrf2 signaling pathway
Amal Mishriki, Amira Karam Khalifa, Dina Anwar Ibrahim, Ghada Hashem, Rashed, Laila Ahmed, Abdelrahman, Sahar Samir, Hesham Mahmoud · 2024 · Figshare
Additional file 1 of Mediating effect of vascular risk factors underlying the link between gestational diabetes and cardiovascular disease
Retnakaran, Ravi, Baiju R. Shah · 2022 · Figshare
Additional file 1 of Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
Tsai, Ming-Lung, Yuan Lin, Lin, Ming-Shyan, Tsai, Tzu-Hsien, Yang, Ning-I, Wang, Chao-Yung, Hsieh, I-Chang, Hung, Ming-Jui, Chen, Tien-Hsing · 2023 · Figshare
Additional file 6 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Yi-lin, Xiaozhuo Xu, Liu, Jing, Wang, Pin-yao, Wang, Xue-li, Feng, Hong-lin, Liu, Cheng-jiang, Han, Xu · 2024 · Figshare
Additional file 1 of Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition
Jacob E. Pruett, Steven J. Everman, Hoang, Ngoc H., Faridah Salau, Lucy C. Taylor, Kristin Shirey Edwards, Jonathan P. Hosler, Alexandra M Huffman, Romero, Damian G., Licy L Yanes-Cardozo · 2022 · Figshare
Additional file 1 of Impaired glucose metabolism and the risk of vascular events and mortality after ischemic stroke: A systematic review and meta-analysis
Nurcennet Kaynak, Valentin Kennel, Torsten Rackoll, Schulze, Daniel, Matthias Endres, Alexander Nave · 2024 · Figshare